Document is current

Article History

Received: 18 December 2021

Accepted: 4 February 2022

First Online: 17 March 2022

Declarations

:

: The study protocol was approved by the institutional review board or an independent ethics committee at each participating centre and was in accordance with the Declaration of Helsinki, the International Conference on Harmonisation-Good Clinical Practice and local laws.

: Not applicable. No individual person’s data is contained within this manuscript.

: Yeon-Hee Park reports consultancy/advisory role for AstraZeneca, Pfizer, Eisai, Roche, Daiichi Sankyo, Eli Lilly and Novartis Pharmaceuticals; patents and royalties from Hanmi Honoraria from AstraZeneca, Pfizer, Eisai, Roche, Daiichi Sankyo and Novartis; and grant/research funding from AstraZeneca, Merck, Pfizer, Novartis, Alteogen and Roche. Yen-Shen Lu reports grants and personal fees from Novartis, personal fees from Pfizer, personal fees from Roche, grants and personal fees from Merck Sharp & Dohme, personal fees from Pfizer, personal fees from Eisai and personal fees from Eli Lilly. Takayuki Ueno reports personal fees from Chugai Pharmaceutical Co., Ltd.; grants and personal fees from Eisai Co., Ltd.; personal fees from AstraZeneca; grants and personal fees from Taiho; and personal fees from Novartis Pharma K.K. Yoichi Naito reports receiving grant funding and/or honoraria from ABBVIE, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol, Chugai, Daiichi Sankyo, Eisai, Eli Lilly, Fuji Film Toyama Chemistry, Gardant, Ono, Mundi, Novartis, Pfizer, Roche, Shionogi, Taiho and Takeda. Han-Byoel Lee is a member of the board of directors of, and has stock and ownership interests at, DCGen, Co., Ltd. Veronique Tan reports personal fees from Bertis, Roche and AstraZeneca. Seock-Ah Im reports receiving research grant from AstraZeneca, Daewoong Pharm, Eisai, Roche and Pfizer for the institution and personal consultation fees from AstraZeneca, Eisai, GSK, Hanmi, Lilly, MSD, Idience, Novartis, Roche and Pfizer, and the research group received drugs from Eisai and Boryung. Yoon-Sim Yap reports receiving travel support and/or honoraria from AstraZeneca, Eisai, Lilly, Novartis, Pfizer, Roche, MSD, Inivata and Specialised Therapeutics. No other disclosures were reported. Wonshik Han is a member of the board of directors of, and has stock and ownership interests at, DCGen, Co., Ltd. Puay Hoon Tan reports advisory role for AstraZeneca and receiving honoraria from Roche, Norvatis and AstraZeneca.